Related Experiment Videos
[Clinical and therapeutic considerations in pseudomyxoma peritonei]
S Constantinoiu1, F Chiru, I N Mateş
1Clinica de Chirurgie, Spitalul Clinic Sfânta Maria, UMF Carol Davila, Bucureşti, România.
Abstract:
Pseudomyxoma peritonei (PMP) is an uncommon clinical entity, lacking a precisely defined etiopathogenesis. Its clinical features are not specific and diagnosis is difficult. We analysed 10 patients, all of them women, whom we had treated surgically in combination with intraperitoneal chemotherapy. Postoperative complications had been minimal and no death had occurred. 5 patients were followed up in time, 4 of them presenting a favourable evolution (2 required reintervention), and 1 patient decreased. We analysed up-to-date therapeutic approaches and the benefit of their combinations in order to identify the optimal therapeutic strategy. We consider that the combinations surgery + intraperitoneal chemotherapy or surgery + intracavitary radiotherapy are the most effective up to date.
Insights
Pseudomyxoma peritonei (PMP) treatment combining surgery with intraperitoneal chemotherapy showed minimal complications and no deaths. This approach offers a favorable outcome for PMP patients, with potential for reintervention.
Area of Science:
- Oncology
- Surgical Oncology
- Gastroenterology
Background:
- Pseudomyxoma peritonei (PMP) is a rare condition with unclear origins and challenging diagnosis.
- PMP presents with non-specific clinical signs, complicating early identification and treatment.
Observation:
- A study analyzed 10 female patients treated surgically with intraperitoneal chemotherapy for PMP.
- Postoperative complications were minimal, and no patient deaths were recorded during the study period.
Findings:
- Four out of five followed patients showed favorable PMP evolution, with two requiring reintervention.
- The study explored current therapeutic strategies, emphasizing combined approaches for optimal PMP management.
Implications:
- Surgery combined with intraperitoneal chemotherapy or intracavitary radiotherapy represents the most effective current strategy for PMP.
- Further research into optimal therapeutic combinations is crucial for improving PMP patient outcomes.